Research Notes
Sencell's sensor lasts a minimum of six months and is the size of a grain, holding against most approved CGM devices from Dexcom, Medtronic and Abbott, which adhere to the skin via a small needle and typically last 7-15 days. In real time, the sensor measures a person's glucose levels, and is much smaller than current alternatives.
Lifecare bases its technology on osmotic pressure. Lifecare describes the approach as providing greater stability and longevity than glucose oxidase and fluorescence-based glucose monitoring, since it avoids enzymes and chemical dyes that degrade over time. Lifecare holds several important patents central to its glucose monitoring technology.
Internally manufacturing Sencell could raise Lifecare's growth by moving CGM implant production from an external contract manufacturer in-house. Lifecare manufactured functional CGM implants internally for the first time, and two passed functional testing in Bergen and completed in-vitro and end-of-line testing at Lifecare Chemistry in Bristol, confirming the shift. Controlled manufacturing requires repeatability, process control, traceability and quality documentation across a larger number of implants; repeatability at that scale determines whether the growth continues.
The production scale-up will supply additional Sencell implants and data for Lifecare's regulatory preparations, covering sterilisation and biocompatibility work. Lifecare's immediate priority remains completing verification and the documentation ahead of the planned pivotal CE-mark clinical investigation.
Three current-generation Sencell implants in the ongoing veterinary study are at six months of implantation in real-world conditions. Independent histological analysis backed the clinical observations and found no adverse or unexpected tissue response.
Sencell, Lifecare's CGM, provides continuous real-time glucose measurement for a minimum of six months through a sensor implanted under a person's skin. The sensor continuously measures the osmotic pressure in its inner sensor chamber, which is directly correlated to the person's glucose levels.
Sencell includes an osmotic pressure sensor core, a transmitter and a mobile medical application reader, and measures glucose in the interstitial fluid. The sensor is injected on the wrist. It operates independently.
Most approved CGM devices from Dexcom, Medtronic and Abbott attach to the skin with a small needle, use glucose oxidase technologies to measure glucose, and have a typical sensor lifespan of 7-15 days. Senseonics offers the implantable Eversense, which measures glucose through a fluorescent chemical reaction and lasts up to 180 days.
Regulatory approval timing is the risk most capable of breaking the Sencell case. Lifecare is not currently providing a specific date for filing the application for regulatory approval of the planned CE-mark clinical study, because the timing of that filing depends on completion of ongoing manufacturing documentation and verification activities that are not yet complete, and the core implant manufacturing process has been transferred to Bergen even though controlled manufacturing has not yet been established.
Lifecare held NOK 30.3 million in cash at quarter end, and its current operating plan is expected to fund operations into Q2 2027. The Q3 2026 operating loss was NOK 12.2 million, compared with NOK 65.9 million in Q3 2025, reflecting a more focused operating model.
